Any general news stories or articles in the media we believe are of interest to you
CML Horizons Conference Lisbon Portugal
May 17th - 19th 2019
Nigel Deekes, as the CML Support Group’s conference delegate, describes highlights from this year’s conference.
Up to 80% of CML patients using tyrosine kinase inhibitors (TKIs) reports muscle complaints. These muscle complaints are strongly related to the presence of fatigue and contributes to both diminished disease control and impaired quality of life. Although the mechanism by which TKIs cause muscle complaints is poorly understood, mitochondrial dysfunction has been suggested to play a pivotal role in TKI-induced cardiac muscle toxicity.
For further reading, follow the link below:
The World Health Organisation (WHO) recently released an alert about batches of ponatinib (Iclusig) that are not authentic.
The technical description of drugs that are not authentic is that they are “Falsified Medicines”.
This situation has similarities with counterfeit versions of well known brands of clothing, trainers or perfumes you sometimes see for sale in street markets at prices way below those for the same products advertised for sale by reputable high street retailers.
A study is being sponsored by UCL School of Pharmacy in London to look into the acceptability of web-based video consultations for patients who are receiving treatment for CML at University College London Hospital UCLH.
To help with this, we are looking for people with CML to take part in a focus group to help the study team understand if the opinions of UCLH patients are similar to those of the wider CML patient population.
In chronic myeloid leukemia (CML) treatment response is determined by measurements of BCR-AB1L transcripts in peripheral blood by quantitative real-time PCR (qRT-PCR) and a 2–5 fold increase is considered a warning sign. The BCR-ABL1 gene is mainly expressed in myeloid cells whereas quantification of BCR-ABL1 is performed on the nucleated cell fraction of peripheral blood. Hence, leukocyte composition of the nucleated cell fraction may affect the result of BCR-ABL1 quantification.
Dasatinib's bioavailability is highly dependent on gastric pH. When proton-pump inhibitors (PPIs) are co-administered with dasatinib, absorption is significantly reduced. Cola intake at the time of drug administration has been demonstrated to lead to relevant increases in the bioavailability for other acid labile drugs during PPI treatment. This manuscript reviews the relevant literature supporting a strategy of temporarily lowering the gastric pH with a carbonated beverage at the time of drug administration.
The UK CML Patient Conference: '22/09 World CML Day' Saturday 22nd September 2018.
The event has now taken place, and video recordings of the main presentations are available on this page.
Click on the link in each agenda item to view the corresponding presentation.
AGENDA
Chronic Myeloid Leukaemia Patient Day. Saturday 22nd September 2018 'World CML Day'.
Organised by Professor Mhairi Copland on behalf of the NCRI CML Sub-Group.
Tessa Holyoake was a giant in the world of CML and her loss to the research community, patients and her fellow specialist clinicians is and will continue to be keenly felt.
Cancer cells are escape artists by nature. They can dodge drugs designed to cripple them due to one of their defining characteristics: their genetic makeup changes rapidly. Cancer cells are constantly evolving, and, given the right mutation, they’re able to evade treatment.